What are the risks of prescribing Yupelri (revefenacin) to a patient with mild chronic obstructive pulmonary disease (COPD) who has glaucoma?

Risk of Yupelri (Revefenacin) in Mild COPD with Glaucoma

Yupelri carries a significant risk of worsening narrow-angle glaucoma and should be used with extreme caution—or avoided entirely—in patients with this condition, regardless of COPD severity. 1

Critical Safety Concerns with Glaucoma

Yupelri (revefenacin) is an anticholinergic medication that can precipitate acute narrow-angle glaucoma, which may cause permanent vision loss if untreated. 1 The FDA drug label explicitly warns about new or worsened eye problems, including acute narrow-angle glaucoma, as a serious side effect. 1

Specific Glaucoma-Related Risks:

• Acute narrow-angle glaucoma symptoms include red eyes, blurred vision, seeing halos or bright colors around lights, eye pain or discomfort, nausea, or vomiting. 1
• Patients must contact their healthcare provider immediately before using another dose if any of these symptoms occur. 1
• The mechanism involves anticholinergic effects causing pupillary dilation and potential angle closure in susceptible individuals. 1

Appropriateness for Mild COPD

For mild COPD specifically, long-acting anticholinergics like Yupelri are generally not indicated as first-line therapy. 2

Treatment Algorithm by COPD Severity:

• Mild COPD patients without symptoms: No drug treatment is recommended. 2
• Mild COPD patients with symptoms: A trial of short-acting β-agonist or short-acting anticholinergic taken as-needed is appropriate, not long-acting agents. 2
• Moderate to severe COPD (FEV1 <60% predicted): Long-acting bronchodilators including anticholinergics are strongly recommended. 3

The 2011 multi-society guideline (ACP/ACCP/ATS/ERS) provides only a weak recommendation for inhaled bronchodilators in patients with FEV1 between 60-80% predicted (mild-moderate COPD), based on low-quality evidence. 3

Additional Anticholinergic Risks

Beyond glaucoma, Yupelri poses other anticholinergic-related risks:

• Urinary retention: Particularly concerning in patients with prostatic hyperplasia or bladder-neck obstruction, with symptoms including difficulty urinating, frequent urination in weak streams, or painful urination. 1
• Paradoxical bronchospasm: Can occur immediately after inhalation, requiring discontinuation. 1
• Drug interactions: Should not be combined with other anticholinergic medications, including beta-blocking agents (even eyedrop formulations). 2, 1

Clinical Recommendation

In a patient with mild COPD and glaucoma, Yupelri should not be prescribed. The combination of:

1. Lack of indication for long-acting anticholinergics in mild COPD 2
2. Serious risk of precipitating acute narrow-angle glaucoma with potential permanent vision loss 1
3. Availability of safer alternatives (short-acting bronchodilators as-needed) for mild disease 2

makes this an inappropriate therapeutic choice. If the patient has narrow-angle glaucoma specifically, this represents an even more critical contraindication requiring absolute avoidance. 1

Safer Alternatives:

• For symptomatic mild COPD: Short-acting β-agonists or short-acting anticholinergics as-needed are preferred initial therapy. 2
• Non-pharmacologic interventions: Smoking cessation is essential at all stages and should be the primary focus. 2
• Ophthalmology consultation: Patients with glaucoma requiring COPD treatment should have coordinated care between pulmonology and ophthalmology. 4